- Home
- VFL vs ACRS Comparison
VFL vs ACRS Comparison
Compare VFL & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFL
- ACRS
- Stock Information
- Founded
- VFL 1993
- ACRS 2012
- Country
- VFL United States
- ACRS United States
- Employees
- VFL N/A
- ACRS N/A
- Industry
- VFL Finance/Investors Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- VFL Finance
- ACRS Health Care
- Exchange
- VFL Nasdaq
- ACRS Nasdaq
- Market Cap
- VFL 117.3M
- ACRS 127.6M
- IPO Year
- VFL N/A
- ACRS 2015
- Fundamental
- Price
- VFL $9.96
- ACRS $1.26
- Analyst Decision
- VFL
- ACRS Strong Buy
- Analyst Count
- VFL 0
- ACRS 7
- Target Price
- VFL N/A
- ACRS $10.67
- AVG Volume (30 Days)
- VFL 38.0K
- ACRS 801.8K
- Earning Date
- VFL 01-01-0001
- ACRS 05-08-2025
- Dividend Yield
- VFL 4.16%
- ACRS N/A
- EPS Growth
- VFL N/A
- ACRS N/A
- EPS
- VFL N/A
- ACRS N/A
- Revenue
- VFL N/A
- ACRS $17,777,000.00
- Revenue This Year
- VFL N/A
- ACRS N/A
- Revenue Next Year
- VFL N/A
- ACRS $425.96
- P/E Ratio
- VFL N/A
- ACRS N/A
- Revenue Growth
- VFL N/A
- ACRS N/A
- 52 Week Low
- VFL $7.93
- ACRS $0.95
- 52 Week High
- VFL $10.77
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- VFL 54.38
- ACRS 43.64
- Support Level
- VFL $9.87
- ACRS $1.20
- Resistance Level
- VFL $10.13
- ACRS $1.46
- Average True Range (ATR)
- VFL 0.12
- ACRS 0.11
- MACD
- VFL 0.05
- ACRS 0.02
- Stochastic Oscillator
- VFL 73.85
- ACRS 41.77
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.